Can cabozantinib be reimbursed by medical insurance?

Cabozantinib (Cabozantinib) is a multi-target tyrosine kinase inhibitor that blocks tumor growth, angiogenesis and metastasis by inhibiting several key targets, including vascular endothelial growth factor receptor (VEGFR), mitogen-activated protein kinase (MAPK), metalloproteinases and hematopoietic stem cell factor receptor (c-Met). Cabozantinib is widely used in the treatment of various malignant tumors such as renal cell carcinoma, thyroid cancer, and liver cancer.

Active substances in cabozantinibCabozantinib is a tyrosine kinase inhibitor. This means that it blocks tyrosine kinase activity. These enzymes can be found in certain receptors on cancer cells, such as the VEGF, MET, and RET receptors, where they activate several processes, including cell division and the growth of new blood vessels to supply the cancer. By blocking the activity of these receptors in cancer cells, drugs can reduce the growth and spread of cancer. Cabozantinib shows benefit in patients with advanced cancer who are not candidates for surgery and have few other treatment options

The original drug Cabozantinib is not marketed in China, so it cannot be included in medical insurance and cannot be reimbursed by medical insurance. The original cabozantinib drug marketed overseas includes Japanese, Turkish and European versions. The price of tablets may be more than 30,000 yuan, and the price of capsule preparations may be more than 40,000 yuan (prices may fluctuate due to exchange rates). There are also generic drugs produced in other countries overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. For example, the price of pharmaceuticals produced by Bangladeshi pharmaceutical factories may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), which is relatively cheap.